TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2857364

Group type: EXPERIMENTAL
Intervention: Dietary vitamin D and calcium (combined index)
Number of subjects: 1954
Study: 31397870

Group type: EXPERIMENTAL
Intervention: 0.05% of energy from IP-TFA
Number of subjects: 0
Study: 29790480

Group type: EXPERIMENTAL
Intervention: Durable polymer Resolute Integrity zotarolimus-eluting stents (ZES)
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer SYNERGY everolimus-eluting stents (EES)
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer Orsiro sirolimus-eluting stents (SES)
Number of subjects: 3514

Group type: COMPARATOR
Intervention: Orsiro sirolimus-eluting stents (SES)
Number of subjects: 3514
Study: 27237768

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1088
Study: 25407695

Group type: EXPERIMENTAL
Intervention: SuperAmma intervention promoting handwashing with soap (HWWS) in intervention villages.
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control villages (no specific intervention mentioned).
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: SuperAmma intervention (reduced from 4 to 2 contact days).
Number of subjects: 345
Study: 23153036

Group type: EXPERIMENTAL
Intervention: Topical application of 20% essential oil of black pepper in aloe vera gel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard nursing care (hot packs with or without vigorous tactile stimulation)
Number of subjects: 120
Study: 19238088

Group type: EXPERIMENTAL
Intervention: Venlafaxine 225-375 mg/day
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60-80 mg/day
Number of subjects: 289
Study: 17989532

Group type: EXPERIMENTAL
Intervention: Allergen specific immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16107993

Group type: EXPERIMENTAL
Intervention: Combination of tenofovir disoproxil fumarate and full-dose didanosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 or neither of the agents (Control)
Number of subjects: 0
Study: 12553483

Group type: EXPERIMENTAL
Intervention: didanosine, stavudine, and nevirapine
Number of subjects: 89
Study: 9794736

Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE)
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Correlation with demographic data and blood pressure
Number of subjects: 2252
Study: 7657105

Group type: EXPERIMENTAL
Intervention: Cyclosporine (5 mg.kg‐1.day‐1)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 182
Study: 2765229

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser excision
Number of subjects: 18

Group type: COMPARATOR
Intervention: Scalpel excision
Number of subjects: 18
Study: 4923930

Group type: EXPERIMENTAL
Intervention: Medazepam 10 mg three times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amylobarbitone 60 mg three times a day
Number of subjects: 0
Study: 31978238

Group type: EXPERIMENTAL
Intervention: Life review (LR) therapy provided by family caregivers
Number of subjects: 19
Study: 31539430

Group type: EXPERIMENTAL
Intervention: Autologous Fresh Whole Blood (FWB) transfusion training
Number of subjects: 3408
Study: 27838475

Group type: COMPARATOR
Intervention: In-person intervention (n=30)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Online intervention (n=50)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Wait-list control (n=30)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Wait-list control (n=50)
Number of subjects: 160
Study: 25921522

Group type: EXPERIMENTAL
Intervention: Physician-directed patient self-management therapeutic strategy based on left atrial pressure (LAP) measured twice daily by an implantable sensor
Number of subjects: 730

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 730
Study: 23563072

Group type: EXPERIMENTAL
Intervention: Logotherapy (My Precious Life program, one session per week for five weeks)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (n=72)
Number of subjects: 142
Study: 22089242

Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (≥ 180 seconds after delivery)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Early clamping (≤ 10 seconds after delivery)
Number of subjects: 400
Study: 19786657

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with leucovorin and fluorouracil after six cycles of mFOLFOX7 (arm 1)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Chemotherapy-free interval (CFI) after six cycles of mFOLFOX7 (arm 2)
Number of subjects: 202
Study: 17482432

Group type: EXPERIMENTAL
Intervention: Quetiapine (50-400 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Risperidone (0.5-2 mg/day)
Number of subjects: 72
Study: 15015164

Group type: EXPERIMENTAL
Intervention: V‐Y advancement
Number of subjects: 35

Group type: COMPARATOR
Intervention: Simple continuous suturing
Number of subjects: 35
Study: 11695749

Group type: EXPERIMENTAL
Intervention: Infant orthopaedics (IO+) - passive maxillary plates during the first year of life
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (IO-) - no passive maxillary plates
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Infant orthopaedics (IO+)
Number of subjects: 2
Study: 9142026

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (inspiratory and expiratory positive airway pressures of 15 and 5 cm H2O, respectively)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP at 10 cm H2O)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure and CPAP
Number of subjects: 27
Study: 7965482

Group type: EXPERIMENTAL
Intervention: Rice-based ORS solution
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard glucose-based ORS solution
Number of subjects: 97
Study: 3655273

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g q.i.d. for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cimetidine 400 mg q.i.d. for 8 weeks
Number of subjects: 42
Study: 29154608

Group type: EXPERIMENTAL
Intervention: Emotional awareness and expression interview
Number of subjects: 75
Study: 26311735

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy-based techniques targeting grief, loss, and change
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 61
Study: 24589500

Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% (IQ3.75%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 23252525

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg if weight ≥30 kg or 12 mg/kg if weight <30 kg) given intravenously every 2 weeks for 12 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo given intravenously every 2 weeks for 12 weeks
Number of subjects: 112
Study: 20517827

Group type: EXPERIMENTAL
Intervention: Magnesium (50 mg/kg bolus followed by 10 mg/kg/h for 24 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (isotonic saline solution)
Number of subjects: 42
Study: 17991790

Group type: EXPERIMENTAL
Intervention: Added external dead space (DS) of 200, 400, and 600 ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control conditions (no added dead space)
Number of subjects: 12
Study: 16268802

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 60 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 90 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (all doses)
Number of subjects: 18
Study: 12132061

Group type: EXPERIMENTAL
Intervention: Fentanyl 35 microg with saline (F)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg + saline (FB)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg + epinephrine 100 microg (FBE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epinephrine 100 microg + saline (FE)
Number of subjects: 80
Study: 10072142

Group type: EXPERIMENTAL
Intervention: CGP 56697 (4 x 4 tablets each containing 20 mg of artemether and 120 mg of benflumetol, given at 0, 8, 24, and 48 hr)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Mefloquine (three tablets of 250 mg at initial diagnosis, followed by two tablets of 250 mg at 8 hr)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: CGP 56697
Number of subjects: 252

Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 252
Study: 7487854

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (modification of negative cognitions)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Provision of information (about oral health and dental treatment)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 52
Study: 1828134

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 74
Study: 6971244

Group type: EXPERIMENTAL
Intervention: Azidocillin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 84
Study: 29309387

Group type: EXPERIMENTAL
Intervention: Positive Pressure Ventilation (PPV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: NO‐PPV
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PPV and NO‐PPV
Number of subjects: 9
Study: 31746528

Group type: EXPERIMENTAL
Intervention: SR-0379 (0.1%) sprayed on skin ulcers once per day for 4 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SR-0379 (0.1%)
Number of subjects: 8
Study: 28958431

Group type: EXPERIMENTAL
Intervention: Holding a load corresponding to 5% body mass in the left hand
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Holding a load corresponding to 5% body mass in the right hand
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Holding a load corresponding to 5% body mass in both hands
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standing without holding a load
Number of subjects: 65
Study: 26934969

Group type: EXPERIMENTAL
Intervention: MOUTh intervention (Managing Oral Hygiene Using Threat Reduction Strategies)
Number of subjects: 0
Study: 24201414

Group type: EXPERIMENTAL
Intervention: 60 ml/h infusion of 30 mg nefopam
Number of subjects: 102

Group type: COMPARATOR
Intervention: 120 ml/h infusion of 30 mg nefopam
Number of subjects: 102

Group type: COMPARATOR
Intervention: 180 ml/h infusion of 30 mg nefopam
Number of subjects: 102
Study: 23050401

Group type: EXPERIMENTAL
Intervention: Periodontitis (n=50)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy non-periodontal subjects (n=25)
Number of subjects: 75
Study: 20031844

Group type: EXPERIMENTAL
Intervention: Basic intervention delivering key evidence-based reminders to home care nurses and patients
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Augmented intervention including basic intervention plus ongoing Hypertension Home Support Program for 12 months
Number of subjects: 845

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 845
Study: 17805582

Group type: EXPERIMENTAL
Intervention: Dipyrone 500 mg PO every 6 h
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 16607045

Group type: COMPARATOR
Intervention: Basal treatment (aspirin 162 mg + cilostazol 200 mg/day)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: ACEI (basal treatment + quinapril 10 mg or perindopril 4 mg/day)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: ARB (basal treatment + losartan 50 mg/day)
Number of subjects: 165
Study: 12943062

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 129

Group type: COMPARATOR
Intervention: Broad-spectrum beta-lactam antibiotics (Control)
Number of subjects: 129
Study: 11004423

Group type: EXPERIMENTAL
Intervention: Language inclusive meta-analyses
Number of subjects: 79

Group type: COMPARATOR
Intervention: Language restricted meta-analyses
Number of subjects: 79
Study: 8851092

Group type: EXPERIMENTAL
Intervention: Laparoscopic technique (n = 150)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Laser technique (n = 100)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Non-laser technique
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Laparoscopic fimbrial eversion with laser (n = 10)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Suture eversion (n = 10)
Number of subjects: 285
Study: 1507816

Group type: EXPERIMENTAL
Intervention: Cordarone (intravenous)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Disopyramide (intravenous)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ajmaline (intravenous)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Verapamil (intravenous)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Novocaine amide (intravenous)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ethacizin (intravenous)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Quinidine (oral)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Kinilentin (oral)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Disopyramide (oral)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Propranolol (oral)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mexitil (oral)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Overall efficacy of antiarrhythmic therapy
Number of subjects: 81
Study: 6343416

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg/h)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal saline (6.5 ml/h)
Number of subjects: 5
Study: 30457058

Group type: EXPERIMENTAL
Intervention: Germination test
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Electrical Conductivity test
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Growth analysis
Number of subjects: 4
Study: 29761751

Group type: EXPERIMENTAL
Intervention: Collaborative care (integrated physical and mental healthcare)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 387
Study: 26822311

Group type: EXPERIMENTAL
Intervention: PRIMA-eDS tool
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3500
Study: 24569914

Group type: EXPERIMENTAL
Intervention: Z-100 at 0.2 µg (Z)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 249
Study: 23122972

Group type: EXPERIMENTAL
Intervention: Insulin glargine dosing strategies (80% of usual dose, call physician for dose, refer to dosing table)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus bolus group (dosing table strategy)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Insulin glargine‐only group
Number of subjects: 401

Group type: COMPARATOR
Intervention: Insulin glargine plus bolus group
Number of subjects: 401
Study: 19543129

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 753

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Number of subjects: 753
Study: 17110457

Group type: EXPERIMENTAL
Intervention: ABX-CBL
Number of subjects: 95

Group type: COMPARATOR
Intervention: ATG
Number of subjects: 95
Study: 16091242

Group type: EXPERIMENTAL
Intervention: Therapeutic immunization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiviral therapy
Number of subjects: 0
Study: 12110028

Group type: EXPERIMENTAL
Intervention: High-flux polysulfone (PS; F 60S)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Super-flux polysulfone (PS; F 500S)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Super-flux cellulosic tri-acetate (CTA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Super-flux cellulosic tri-acetate with filtered dialysate (CTA(f))
Number of subjects: 74

Group type: COMPARATOR
Intervention: Clinical events
Number of subjects: 74
Study: 10434832

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg i.v.
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% saline i.v. (placebo)
Number of subjects: 80
Study: 7568532

Group type: EXPERIMENTAL
Intervention: Consumer case management services
Number of subjects: 91
Study: 2148767

Group type: EXPERIMENTAL
Intervention: Flat position for 15 minutes followed by head elevated 30 degrees for 15 minutes
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Flat position for 15 minutes followed by head elevated 30 degrees with knee gatch elevated for 15 minutes
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Flat position for 15 minutes followed by reverse Trendelenberg for 15 minutes
Number of subjects: 4
Study: 7032305

Group type: EXPERIMENTAL
Intervention: Rotating gratings (15 min per week for 10 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Blank rotating disk (same duration as treatment group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Weekly acuity evaluation without treatment (second control group)
Number of subjects: 42
Study: 30665198

Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT) directed at the right-side ankle and foot
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment (CONTROL group)
Number of subjects: 84
Study: 26249232

Group type: EXPERIMENTAL
Intervention: ONO-2952 (3, 10, 30, 100, 200, or 400 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ONO-2952 (30, 60, or 100 mg/d)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ONO-2952 (10 mg and 200 mg) under fasted and fed conditions
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 23526594

Group type: EXPERIMENTAL
Intervention: Ice pack
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cold-water immersion
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both modalities
Number of subjects: 41
Study: 22134226

Group type: EXPERIMENTAL
Intervention: Cold vibration device placed 5 to 10 cm proximally during venipuncture
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care (primarily vapocoolant spray)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cold vibration device
Number of subjects: 81
Study: 19138437

Group type: EXPERIMENTAL
Intervention: High fish oil (HFO) meal (2.2 g fish oil)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Reference (REF) meal (0.3 g fish oil)
Number of subjects: 11
Study: 17350451

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (including early routine catheterisation and revascularisation)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Selective invasive strategy (catheterisation if refractory angina or recurrent ischaemia)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1200
Study: 15539706

Group type: EXPERIMENTAL
Intervention: Thiotepa (15 mg on days 1, 3, and 5 after percutaneous pericardiocentesis)
Number of subjects: 33
Study: 11394556

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise program (6 months, twice per week for 60 min)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 94
Study: 9480997

Group type: EXPERIMENTAL
Intervention: beclomethasone three times daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: theophylline twice daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 102
Study: 7818840

Group type: EXPERIMENTAL
Intervention: Captopril (angiotensin-converting enzyme inhibitor)
Number of subjects: 10800

Group type: COMPARATOR
Intervention: Conventional antihypertensive therapy (diuretics or beta-blockers)
Number of subjects: 10800
Study: 3339551

Group type: EXPERIMENTAL
Intervention: 3M style 34R plano-convex (reverse) optic posterior chamber lens
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3M style 34S convex‐plano optic posterior chamber lens
Number of subjects: 0
Study: 30980399

Group type: EXPERIMENTAL
Intervention: Sorafenib (lower dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autophagy inhibition (genetically or pharmacologically) combined with Sorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of hydroxychloroquine and sorafenib
Number of subjects: 0
Study: 28193219

Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1951
Study: 25479969

Group type: EXPERIMENTAL
Intervention: Covert PBA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Overt PBA
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no armour)
Number of subjects: 8
Study: 23256574

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 1 - 3 mg/24 h
Number of subjects: 198
Study: 22091993

Group type: EXPERIMENTAL
Intervention: Transvaginal Natural Orifice Transluminal Endoscopic Surgery (NOTES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 12
Study: 18438227

Group type: EXPERIMENTAL
Intervention: Pre-exercise energy supplement (combination of branched chain amino acids, creatine, taurine, caffeine, and glucuronolactone)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pre-exercise energy supplement
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17067583

Group type: EXPERIMENTAL
Intervention: Microsurgical removal of the pronucleus located at the farthest position to the second polar body (intervention group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Triploid control group (control group)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Manipulated embryos (intervention group)
Number of subjects: 114
Study: 12895612

Group type: EXPERIMENTAL
Intervention: Combined procedure (Group A)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Valve procedure alone (Group B)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 12907538

Group type: EXPERIMENTAL
Intervention: Sequential i.v./po moxifloxacin monotherapy (400 mg qd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: i.v./po co-amoxiclav (1.2 g i.v./625 mg po tid) with or without clarithromycin (500 mg bid)
Number of subjects: 0
Study: 10200750

Group type: EXPERIMENTAL
Intervention: Enhanced acute-phase treatment for depression
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine treatment for depression
Number of subjects: 156